

Oral Presentations at 2017 ASH Annual Meeting

Presentation	Presenter	Time	Location
Genetically-Defined Diffuse Large B-Cell Lymphoma Subsets Arise By Distinct Pathogenetic Mechanisms and Predict Outcome	Bjoern Chapuy, MD, PhD	8:00 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, C101 Aud
Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic GVHD	Yusuke Kamihara, MD, PhD	8:00 a.m.	Georgia World Congress Center, Bldg B, Lvl 3, B308-B309
Special Scientific Symposium: Clonal Hematopoiesis Influences Cardiovascular Risk	Benjamin Ebert, MD, PhD	9:30 – 11:00 a.m.	Georgia World Congress Center, Bldg C, Lvl 3, Georgia BR 1-3
Hscb, a Mitochondrial Iron-Sulfur Cluster Assembly Co-Chaperone, Is a Novel Candidate Gene for Congenital Sideroblastic Anemia	Sarah Ducamp, PhD*	9:45 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B211-B212
Career Development Lunch Sessions Program: Trainee Activities and Services; Clinical Malignant Hematology/BMT	Joseph Antin, MD	11:15 a.m. – 12:15 p.m.	Omni Hotel at CNN Center, Int'l Blrm. F No. Twr. M2
Uncoding the Genetic Heterogeneity of MDS Myelodysplastic Syndromes: Understanding the Current Treatment Landscape	R. Coleman Lindsley, MD, PhD	2:00 – 3:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 3, Murphy BR 3-4
Special Scientific Symposium: DNA Repair Targets in Bone Marrow Failure and Cancer	Alan D. D'Andrea, MD	2:00 – 3:30 p.m.	Georgia World Congress Center, Bldg C, Lvl 3, Georgia BR 1-3
SCI-41 Congenital Sideroblastic Anemias: Iron and Heme Lost in Mitochondrial Translation	Mark D. Fleming, MD, DPhil	2:00 – 3:30 p.m.	Georgia World Congress Center, Bldg C, Lvl 2, C211-C213
Biology and Management of Lymphoplasmacytic Lymphoma Indolent Lymphoma: How Understanding Disease Biology Is Influencing Clinical Decision-Making	Jorge J. Castillo, MD	4:00 – 5:30 p.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C2-C3
Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation	Matthew Davids, MD, MMSc	5:00 p.m.	Georgia World Congress Center, Bldg C, Lvl 2, C211-C213
Splicing Modulation Perturbs Key Survival Pathways and Sensitizes Chronic Lymphocytic Leukemia to Venetoclax Treatment	Elisa Ten Hacken, PhD	5:15 p.m.	Georgia World Congress Center, Bldg C, Lvl 1, C101 Aud

Oral Presentations at 2017 ASH Annual Meeting

Presentation	Presenter	Time	Location
Knowles' Adult Learning Theory Special-Interest Session Hematology Course Directors' Workshop	Jennifer C. Kesselheim, MD, MEd*	7:00 – 9:00 a.m.	Omni Hotel at CNN Center, Grand Blrm A, No. Twr, M4
Insights Into Hodgkin Lymphoma Biology: Implications for Prognosis and Novel Therapeutics Hodgkin Lymphoma: New Insights and New Approaches	Margaret Shipp, MD	7:30 – 9:00 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C2-C3
Individualizing Therapy in Chronic Lymphocytic Leukemia How Should We Sequence and Combine Novel Therapies in CLL?	Matthew S. Davids, MD, MMSc	7:30 – 9:00 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C1
Dilemmas in Pediatric Hematologic Malignancy: Incorporation of Non-Chemotherapeutic Agents in Pediatric Acute Lymphocytic Leukemia	Lewis Silverman, MD*	7:30 – 9:00 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C4
Fetal Hemoglobin (HbF) Silencer BCL11A Acts through a Novel DNA-Motif in the Gamma-Globin Promoters, Simplifying the Model for Hemoglobin Switching	Nan Liu, PhD*	7:30 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B213-B214
Avatrombopag, a Novel Thrombopoietin Receptor Agonist, Increases Platelet Counts without Increasing Platelet Activation in Patients with Thrombocytopenia Due to Chronic Liver Disease	Andrew L Frelinger III, PhD*	7:45 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B216-B217
Hospice Use Among Patients with Myeloma	Oreofe O. Odejide, MD, MPH	8:15 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B206
High-Resolution CRISPR Functional Genomics Reveals Critical Vulnerabilities of the NuRD Complex for Fetal Hemoglobin Control	Falak Sher, PhD	8:15 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B213-B214
Genomic Discovery and Clonal Tracking in Multiple Myeloma By Cell Free DNA Sequencing	Jens Lohr, MD, PhD	8:30 a.m.	Georgia World Congress Center, Bldg B, Lvl 3, B302-B303
Special Scientific Symposium on Targeted Therapy: What Is the Best Target? Targeting Regulators of Differentiation	Kimberly Stegmaier, MD*	9:30 – 11:00 a.m.	Georgia World Congress Center, Bldg A, Lvl 4, A411-A412
SCI-41 Congenital Sideroblastic Anemias: Iron and Heme Lost in Mitochondrial Translation	Mark D. Fleming, MD, DPhil*	9:30 - 11:00 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B216-B217

Continued over

Oral Presentations at 2017 ASH Annual Meeting

Presentation	Presenter	Time	Location
Biology and Management of Lymphoplasmacytic Lymphoma Indolent Lymphoma: How Understanding Disease Biology Is Influencing Clinical Decision-Making	Jorge J. Castillo, MD	9:30 – 11:00 a.m.	Georgia World Congress Center, Bldg B, Lvl 5, Murphy BR 3-4
Hedgehog Pathway Mutations Drive Oncogenic Transformation in High-Risk T-Cell Acute Lymphoblastic Leukemia	Melissa A. Burns, MD*	9:30 a.m.	Georgia World Congress Center, Bldg C, Lvl 2, C211-C213
Defining the Diversity and Specificity of Neoantigen-Specific T Cells in Chronic Lymphocytic Leukemia	Zhuting Hu, PhD	9:45 a.m.	Georgia World Congress Center, Bldg B, Lvl 3, B302-B303
Next Generation Sequencing Identifies Smoldering Multiple Myeloma Patients with a High Risk of Disease Progression	Mark Bustoros, MD	9:45 a.m.	Georgia World Congress Center, Bldg B, Lvl 3, B304-B305
Plenary Scientific Session: Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)	Daniel J. DeAngelo, MD, PhD	2:00 – 4:00 p.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C2-C3
Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease	Sarah Nikiforow, MD, PhD	4:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 2, B211-B212
A First in Class APRIL Fully Blocking Antibody Targets Novel Immune Regulation of APRIL in Multiple Myeloma: Further Therapeutic Implication	Yu-Tzu Tai, PhD	4:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 3, B308-B309
NETs: “Nuclear” Weapons of Inflammation	Denisa D. Wagner, PhD*	4:30 - 6:00 p.m.	Georgia World Congress Center, Bldg B, Lvl 3, B302-B303
A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients	Matthew S. Davids, MD, MMSc	5:15 p.m.	Georgia World Congress Center, Bldg B, Lvl 5, Murphy BR 3-4
Extra-Corporeal Photopheresis Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Efficacy, Safety and Immune Correlates	John Koreth, MBBS, DPhil	5:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 2, B211-B212
Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates	Jennifer Whangbo, MD, PhD*	6:00 – 8:00 p.m.	Georgia World Congress Center, Bldg A, Lvl 1, Hall A2

Oral Presentations at 2017 ASH Annual Meeting

Presentation	Presenter	Time	Location
Drugs to Prevent and Treat Relapse Following Allogeneic Stem Cell Transplantation	Robert J. Soiffer, MD	7:00 – 8:30 a.m.	Georgia World Congress Center, Bldg B, Lvl 4, B405-B407
When Graft Versus Tumor Fails: The Biology and Treatment of Relapse After Allogeneic Stem Cell Transplantation		2:45 – 4:15 p.m.	Georgia World Congress Center, Bldg C, Lvl 3, Georgia BR 1-3
Individualizing Therapy in Chronic Lymphocytic Leukemia	Matthew S. Davids, MD, MMSc	7:00 – 8:30 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C2-C3
How Should We Sequence and Combine Novel Therapies in CLL?			
In Vitro and pre-Clinical In Vivo Evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53-Wild-Type T-Cell Lymphomas That Are Targetable with the α -Helical p53 Stapled Peptide Alrn-6924	Raphael Koch, MD	7:00 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B213-B214
Dilemmas in Pediatric Hematologic Malignancy: Incorporation of Non-Chemotherapeutic Agents in Pediatric Acute Lymphocytic Leukemia	Lewis B. Silverman, MD*	7:00 – 8:30 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C1
Novel Mechanisms Underlying IMiDs Resistance in Multiple Myeloma: Therapeutic Implications	Jiye Liu, PhD	8:15 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B211-B212
Uncoding the Genetic Heterogeneity of MDS	R. Coleman Lindsley, MD, PhD	10:30 a.m. – 12:00 p.m.	Georgia World Congress Center, Bldg B, Lvl 5, Murphy BR 3-4
Myelodysplastic Syndromes: Understanding the Current Treatment Landscape			
Insights Into Hodgkin Lymphoma Biology: Implications for Prognosis and Novel Therapeutics	Margaret A. Shipp, MD	10:30 a.m. – 12:00 p.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C2-C3
Hodgkin Lymphoma: New Insights and New Approaches			
Identification and Validation of Molecular Markers of Tumor Cell Resistance to Natural Killer Cells through CRISPR-Based Screens and Large-Scale Phenotypic Screens of Pooled Tumor Cell Lines	Michal Sheffer, PhD	11:30 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, C108-C109
PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström's Macroglobulinemia	Mariateresa Fulciniti, PhD	11:45 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, C101 Aud

Continued over

Monday, December 11, 2017

Oral Presentations at 2017 ASH Annual Meeting

Presentation	Presenter	Time	Location
Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs	Gregory A. Abel, MD, MPH	11:45 a.m.	Georgia World Congress Center, Bldg C, Lvl 2, C208-C210
GLS-409, a Synergistic Inhibitor of Both P2Y1 and P2Y12: Efficacy in a Canine Model of Recurrent Coronary Thrombosis and Reversibility of Human Platelet Inhibition	Elena Smolensky Koganov, PhD	11:45 a.m.	Georgia World Congress Center, Bldg B, Lvl 2, B207-B208
Health Related Quality of Life and Fatigue Improve on Second Line Treatments in Pediatric Immune Thrombocytopenia (ITP)	Rachael F. Grace, MD*	3:00 p.m.	Georgia World Congress Center, Bldg C, Lvl 2, C211-C213
A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia	Shruti Bhatt, PhD	4:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 4, B401-B402
Resistance to SL-401 in AML and BPDCN Is Associated with Loss of the Diphthamide Synthesis Pathway Enzyme DPH1 and Is Reversible By Azacitidine	Jason Stephansky	5:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 2, B207-B208
Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown, γ -Globin Induction and Simultaneous Repression of β -Globin for the Potential Treatment of Sickle Cell Disease	David A. Williams, MD*	6:00 – 8:00 p.m.	Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
Fetal Erythropoiesis Is Defective in Rpl11 Heterozygous Mice and Increases in Severity in Young Animals	Carl D. Novina, MD, PhD	6:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 3, B302-B303
Vcp-Regulated Homologous Recombination Represents a New Druggable Vulnerability in Acute Myeloid Leukemia	Lina Benajiba, MD*	7:00 p.m.	Georgia World Congress Center, Bldg C, Lvl 1, C101 Aud
The Activated TGF β Pathway in Shwachman Diamond Syndrome Impairs Hematopoiesis and Is Down-Regulated By Deletion of 7q	Melisa Ruiz-Gutierrez, MD, PhD*	7:15 p.m.	Georgia World Congress Center, Bldg B, Lvl 3, B302-B303
GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study	Daniel J. DeAngelo, MD, PhD	7:30 p.m.	Georgia World Congress Center, Bldg B, Lvl 5, Murphy BR 1-2

Tuesday, December 12, 2017

William Dameshek Prize	Recipient: Benjamin Ebert, MD, PhD	9:30 – 9:45 a.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C2-C3
Best of ASH	Scott Armstrong, MD*	11:30 a.m. – 1:00 p.m.	Georgia World Congress Center, Bldg C, Lvl 1, Hall C2-C3

* Dana-Farber/Boston Children's Cancer and Blood Disorders Center